ReviewImmunology2010
Major histocompatibility complex class I binding predictions as a tool in epitope discovery.
Review in Immunology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Immunoinformatics prediction of potential B-cell and T-cell epitopes as effective vaccine candidates for eliciting immunogenic responses against Epstein-Barr virus.Biomedical journal · 2021Pooled it
- Plant-Based Oral Vaccines: Molecular Biotechnology Approaches Toward Functional Food-Based Immunization.Molecular biotechnology · 2026Review
- Computational design of HLA class I superbinders for broad T cell immunogenicity.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Immunoinformatics-based design of a next generation multi-epitope vaccine candidate against Shigella boydii using a hierarchical subtractive proteomics approach.Scientific reports · 2025Article
- Neoantigen-based immunotherapy: advancing precision medicine in cancer and glioblastoma treatment through discovery and innovation.Exploration of targeted anti-tumor therapy · 2025Review
- Vaccine Designing Technology against Leishmaniasis: Current Challenges and Implication.Current drug discovery technologies · 2025Review
- ConvNeXt-MHC: improving MHC-peptide affinity prediction by structure-derived degenerate coding and the ConvNeXt model.Briefings in bioinformatics · 2024Article
- A Continuous Extension of Gene Set Enrichment Analysis Using the Likelihood Ratio Test Statistics Identifies Vascular Endothelial Growth Factor as a Candidate Pathway for Alzheimer's Disease via ITGA5.Journal of Alzheimer's disease : JAD · 2024Article
- Harnessing antibody-mediated recognition of the intracellular proteome with T cell receptor-like specificity.Frontiers in immunology · 2024Review
- Quantitative measurement of the requirement of diverse protein degradation pathways in MHC class I peptide presentation.Science advances · 2023Article
- A Multistage Antigen Complex Epera013 Promotes Efficient and Comprehensive Immune Responses in BALB/c Mice.Vaccines · 2023Article
- Role of MHC class I pathways inFrontiers in cellular and infection microbiology · 2023Review
- The Intracellular Proteome as a Source for Novel Targets in CAR-T and T-Cell Engagers-Based Immunotherapy.Cells · 2022Review
- Improving MHC class I antigen-processing predictions using representation learning and cleavage site-specific kernels.Cell reports methods · 2022Article
- Predicting MHC class I binder: existing approaches and a novel recurrent neural network solution.Briefings in bioinformatics · 2021Article
- Identification of SARS-CoV-2 CTL epitopes for development of a multivalent subunit vaccine for COVID-19.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2021Article
- A comprehensive review and performance evaluation of bioinformatics tools for HLA class I peptide-binding prediction.Briefings in bioinformatics · 2020Review
- Immunoinformatics: Predicting Peptide-MHC Binding.Annual review of biomedical data science · 2020Article
- High-Throughput Prediction of MHC Class I and II Neoantigens with MHCnuggets.Cancer immunology research · 2020Article
- Immunoinformatics and Vaccine Development: An Overview.ImmunoTargets and therapy · 2020Review
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
summaryOver the last decade, in silico models of the major histocompatibility complex (MHC) class I pathway have developed significantly. Before, peptide binding could only be reliably modelled for a few major human or mouse histocompatibility molecules; now, high-accuracy predictions are available for any human leucocyte antigen (HLA) -A or -B molecule with known protein sequence. Furthermore, peptide binding to MHC molecules from several non-human primates, mouse strains and other mammals can now be predicted. In this review, a number of different prediction methods are briefly explained, highlighting the most useful and historically important. Selected case stories, where these 'reverse immunology' systems have been used in actual epitope discovery, are briefly reviewed. We conclude that this new generation of epitope discovery systems has become a highly efficient tool for epitope discovery, and recommend that the less accurate prediction systems of the past be abandoned, as these are obsolete.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.